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Background and purpose: Low levels of insulin-like growth factor I (IGF-I) predispose to atherosclerosis
and may therefore increase the risk of stroke. Low levels have also been found to influence the outcome of
cardiovascular and cerebrovascular disease. A polymorphism in the promoter region of the IGF-I gene
influences IGF-I levels. Non-carriers of the 192 bp allele have lower levels of IGF-I compared with 192 bp
allele carriers. We studied the IGF-I polymorphism in relation to the risk of stroke and survival after stroke.
Methods: We studied 6808 subjects of the Rotterdam Study, who were followed for the occurrence of
stroke and death after stroke. Subjects were grouped according to the 192 bp allele of IGF-I into non-
carriers, heterozygotes, and homozygotes. The risk of stroke and survival after stroke was studied using
Cox regression analysis, adjusting for age and sex, with homozygotes for the wildtype allele as the
reference.
Results: Non-carriers had a relative risk of 0.8 (95% CI: 0.6 to 1.0) for the occurrence of any stroke and
0.7 (95% CI: 0.5 to 1.0) for ischaemic stroke. For non-carriers, the relative risk of death after any stroke
was 1.5 (95% CI: 1.0 to 2.2). After an ischaemic stroke, this relative risk was 1.5 (95% CI: 0.9 to 2.6) and
after a haemorrhagic stroke 5.2 (95% CI: 1.3 to 21.5).
Conclusions: Our study suggests that IGF-I is a significant determinant of survival after stroke.
I
nsulin-like growth factor I (IGF-I) appears to be involved
in the development of atherosclerosis and cardiovascular
disease because of its role in tissue repair and cell
proliferation.1–4 Also, IGF-I induces the synthesis of elastin
and prevents apoptosis of vascular smooth muscle cells.5–7
Therefore, low levels might be a risk factor for stroke.
Expression of IGF-I is increased after hypoxic injury in
regions with neuronal loss8 and animal studies have found
that administration of IGF-I reduces infarct volume and
improves neurological function after ischaemia.8–10 This
suggests that IGF-I levels may be involved in outcome after
stroke. Indeed, it was found that IGF-I levels are lower after
cerebral ischaemia,11 12 and low levels are associated with a
poor outcome after ischaemic stroke11 as well as myocardial
infarction (MI).13 We have previously found that a poly-
morphism in the promoter region of the IGF-I gene, located
on chromosome 12q, is associated with plasma IGF-I levels.
Non-carriers of the 192 bp (wildtype) allele of this poly-
morphism have lower plasma IGF-I levels compared with
192 bp allele carriers.14 Also, non-carriers of the 192 bp allele
were found to have an increased risk of MI14 and an increase
in mean intima-media thickness of the common carotid
arteries and mean pulse wave velocity.15 We studied the
association between the IGF-I promoter polymorphism and
the risk of stroke, as well as survival after stroke, for any
stroke, ischaemic stroke, and haemorrhagic stroke.
METHODS
Study population
The present study was performed as part of the Rotterdam
Study, an ongoing prospective population based cohort study
on chronic and disabling diseases in the elderly.16 The medical
ethics committee of Erasmus Medical Center, Rotterdam,
approved the study. Participants gave written informed
consent and permission to retrieve information from treating
physicians. A total of 7983 subjects participated in this study
(78% response rate), all aged 55 years and over at baseline.
IGF-I genotyping was successfully performed in 7012 (68.5%)
individuals using frozen serum samples collected at baseline.
The genotyping success rate was 87.8%. No DNA was
available for 948 subjects and genotyping failed in 23
subjects. Serum IGF-I levels were assessed in a randomly
selected subgroup of 406 subjects, as described earlier.17
Participants with a stroke before baseline were excluded
from the analyses (n=258). Our study population therefore
comprised 6808 individuals (85%). The sample appeared to
be random, as we did not find differences between
participants with and without a known IGF-I genotype with
regard to demographic or cardiovascular characteristics.
Measurements and diagnosis of stroke
Baseline data were collected from 1990 until 1993.
Measurements and definitions of body mass index (BMI),
hypertension, cholesterol levels, and diabetes mellitus are
described elsewhere.18 A previous stroke was determined
during the baseline interview by asking ‘‘did you ever suffer
from a stroke, diagnosed by a physician?’’. Medical records of
subjects who answered ‘‘yes’’ were checked in order to verify
the diagnosis.19
Follow up started at baseline and lasted until 1 January
2002 for the present study. Once subjects enter the
Rotterdam Study, they are continuously monitored for major
events through automated linkage of the study database with
files from general practitioners (GPs) and the municipality.
Also nursing home physicians’ files are scrutinised. For
reported events, additional information (including brain
images) is obtained from hospital records. Trained research
physicians reviewed information on all possible strokes
and transient ischaemic attacks. An experienced stroke
Abbreviations: BMI, body mass index; CV death, cardiovascular death
after stroke; IGF-I, insulin-like growth factor I; GP, general practitioner;
MI, myocardial infarction
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neurologist (PJK) verified all diagnoses. Subarachnoid
haemorrhages and retinal strokes were excluded. Follow up
was completed until January 1, 2001 for 97.1% of all potential
person years.20 Ischaemic strokes were diagnosed when a
patient had typical symptoms and a CT or MRI performed
within 4 weeks ruled out other diagnoses or when indirect
evidence (deficit limited to one limb or completely resolved
within 72 h, atrial fibrillation in the absence of antic-
oagulants) suggested an ischaemic stroke. Haemorrhagic
stroke was diagnosed when a relevant haemorrhage was
shown on CT or MRI scan, or when the subject permanently
lost consciousness or died within hours after onset of focal
signs. If a stroke did not match these criteria, it was classified
as unspecified. Neuroimaging was available for 61% of all
events. For ischaemic stroke, this was 91% and for haemor-
rhagic stroke 78%. Ischaemic stroke was subclassified into
large vessel disease, small vessel disease, and stroke due to a
cardio-embolic source using the TOAST criteria.21
Information on mortality was obtained from the GPs and
hospitals and also regularly from the municipal health
authorities in Rotterdam. Two research physicians indepen-
dently coded all events according to the International
Classification of Diseases, 10th edition (ICD-10).22 We
defined cardiovascular mortality as death from ischaemic
heart disease (I20–25), ventricular fibrillation (I49), con-
gestive heart failure (I50), cerebrovascular disease (I60–67),
peripheral artery disease (I70–74), hypertensive heart disease
(I10–15), disorders of the aorta, arteries, arterioles, and
capillaries (I70–79) or mesenteric atherosclerosis (K55),
sudden cardiac death (I46), or sudden death unknown
(R96). The IGF-I gene promoter polymorphism was geno-
typed as described previously, without knowledge of the
clinical diagnosis.14
Data analysis
Hardy-Weinberg equilibrium of the IGF-I promotor poly-
morphism genotypes was tested using the GENEPOP
package.23 Baseline characteristics were compared using
univariate ANOVA or x2 statistics. Cox proportional hazards
regression analysis was used to assess the relative risk of
stroke, as well as the relative risk of death after stroke, with
the homozygous carriers of the wildtype allele (192 bp) as the
reference group (SPSS 11.0; SPSS, Chicago, IL). We tested the
proportional hazard assumption using the log-log survival
curve (SPSS 11.0) and goodness-of-fit using S-PLUS 6.0
(MathSoft, Cambridge, MA). All analyses were adjusted for
age and sex.
RESULTS
All IGF-I genotype and allele proportions were in Hardy-
Weinberg equilibrium. Table 1 shows the baseline character-
istics of the study population stratified by IGF-I genotype.
Serum total IGF-I levels were significantly lower in non-
carriers of the 192 bp allele compared with homozygous and
heterozygous carriers (p,0.001). No significant differences
were observed between the genotype groups and age, sex, or
other cardiovascular risk factors.
During a mean follow up of 8 years, we observed 637
incident stroke cases in our study population. We classified
357 as ischaemic stroke, 59 as haemorrhagic stroke, and 221
Table 1 Baseline characteristics of the study population
stratified by IGF-1 genotype
IGF-1
192/192 192/2 2/2
Number of subjects 2985 3014 809
Age 69.5¡9.2 69.3¡9.2 69.5¡9.4
Sex, n (% male) 1191 (39.9) 1202 (39.9) 310 (38.3)
SBP (mm Hg) 139.1¡22.1 139.3¡22.5 139.0¡22.3
DBP (mm Hg) 73.6¡11.4 73.9¡11.8 73.3¡11.4
Hypertension n (%) 981 (33.8) 998 (34.2) 256 (32.7)
Diabetes, n (%) 287 (9.6) 316 (10.5) 74 (9.1)
Current smoking, 656 (22.7) 676 (23.3) 159 (20.2)
n (%)
BMI (kg/m2) 26.3¡3.8 26.2¡3.6 26.2¡3.7
Total cholesterol 6.6¡1.3 6.6¡1.2 6.6¡1.2
(mmol/l)
HDL cholesterol 1.3¡0.4 1.3¡0.4 1.4¡0.4
(mmol/l)
Serum total IGF-I 18.5¡7.0 18.4¡7.8 14.6¡5.8
levels (nmol/l)* (n = 130) (n = 136) (n = 140)
*Determined in a randomly drawn subgroup; significantly different from
homozygous and heterozygous carriers (p,0.001).
All values are presented as unadjusted means¡standard deviation or
total numbers (percentages). DBP, diastolic blood pressure; SBP, systolic
blood pressure.
Table 2 Relative risk of stroke and stroke subtypes in relation to IGF-1 genotype
IGF-I genotype
192/192 (n = 2985) 192/2 (n = 3014) 2/2 (n = 809)
n RR n RR (95% CI) n RR (95% CI)
All strokes 266 1.0 (reference) 229 0.9 (0.7 to 1.0) 56 0.8 (0.6 to 1.0)
Ischaemic strokes 156 1.0 (reference) 131 0.8 (0.7 to 1.1) 30 0.7 (0.5 to 1.0)
Haemorrhagic strokes 22 1.0 (reference) 25 1.1 (0.6 to 2.0) 6 1.0 (0.4 to 2.4)
Unspecified stroke 88 1.0 (reference) 73 0.8 (0.6 to 1.1) 20 0.8 (0.5 to 1.3)
Large vessel disease 12 1.0 (reference) 13 1.1 (0.5 to 2.4) 5 1.5 (0.5 to 4.4)
Cardio-embolic stroke 26 1.0 (reference) 22 0.8 (0.5 to 1.5) 8 1.1 (0.5 to 2.5)
Small vessel disease 21 1.0 (reference) 18 0.9 (0.5 to 1.6) 3 0.5 (0.2 to 1.7)
n, total number of cases; RR, relative risk with 95% confidence interval, adjusted for age and sex.
1.0
0.8
0.6
0.4
0.0
0.2
108
Survival after first stroke in years
C
um
ul
at
iv
e 
su
rv
iv
al
640 2
192/192
192/–
–/–
1
2
3
1
2
3
Figure 1 Cumulative survival after any stroke.
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as unspecified. We had data on the IGF-I genotype for 551
(86.5%) cases. This corresponds to the proportion of success-
fully performed genotyping in subjects overall (87.8%).
Table 2 shows the absolute numbers of strokes and risk
estimates for each genotype group for any, ischaemic,
haemorrhagic, and unspecified stroke. Non-carriers were
found to have a risk of 0.8 (95% CI: 0.6 to 1.0, p=0.05) for
the occurrence of any stroke and 0.7 (95% CI: 0.5 to 1.0,
p=0.07) for ischaemic stroke, compared with homozygote
carriers of the 192 bp allele. In this table, we also show the
risk of subtypes of ischaemic stroke for different IGF-I
genotypes. We found that non-carriers had a relative risk of
large vessel disease of 1.5 (95% CI: 0.5 to 4.4, p=0.4), a
relative risk of cardio-embolic stroke of 1.1 (95% CI: 0.5 to
2.5, p=0.8), and a relative risk of small vessel disease of 0.5
(95% CI: 0.2 to 1.7, p=0.3). All values were adjusted for age
and sex. Adjusting for additional risk factors (smoking
status, diabetes mellitus, hypertension, BMI, and total
cholesterol level) did not alter these results.
Figure 1 shows the cumulative survival in years after any
stroke. The cumulative survival is lowest for non-carriers.
Also, it is shown that the effect of the IGF-1 genotype on
survival is strongest in the first months after a stroke. The
same was found for survival after ischaemic stroke, haemor-
rhagic stroke, and unspecified stroke. Table 3 describes the
absolute numbers of death after a stroke and the relative risk
for each genotype. For non-carriers, we found that the
relative risk of death after any stroke was 1.5 (95% CI: 1.0 to
2.2, p=0.03), after ischaemic stroke 1.5 (95% CI: 0.9 to 2.6,
p=0.1), and after haemorrhagic stroke 5.2 (95% CI: 1.3 to
21.5, p=0.02) compared with homozygous carriers. Numbers
were too small for analyses in subclassifications of ischaemic
stroke. The risk estimates remained similar after adjusting for
the additional risk factors.
We also analysed the effect of IGF-I on survival in the
overall population, with exclusion of prevalent and incident
stroke (not shown). The mean survival time in the cohort
(until death or end of follow up) was 8.5 years for all three
genotypes, adjusted for age and sex. We found a relative risk
of 1.0 (95% CI: 0.9 to 1.1) for heterozygote carriers and of 1.0
(95% CI: 0.8 to 1.1) for non-carriers compared with
homozygous carriers of the 192 bp allele.
Next, we analysed the effect of the IGF-I genotype on
cardiovascular death after stroke (CV death). For any stroke,
ischaemic stroke, and haemorrhagic stroke, the absolute
numbers of CV death were 20 (35.7%), 8 (26.7%), and 4
(66.7%) in non-carriers, compared with 71 (26.7%), 32
(20.5%) and 8 (36.4%) in homozygous carriers, respectively
(table 4). The highest relative risk for CV death was 3.0 (95%
CI: 0.6 to 14.5), which was found in non-carriers after
haemorrhagic stroke. However, this finding was not sig-
nificant. Also, the relative risk of CV death after any,
ischaemic, or unspecified stroke, was not significant
(table 4). The proportional hazard assumption was met for
all previously shown analyses.
DISCUSSION
This is the first investigation of the IGF-I promoter
polymorphism and stroke. In this large population based
cohort study, we found a protective effect for non-carriers of
the 192 bp allele of the IGF-I polymorphism on any and
ischaemic stroke, although this was not significant. However,
we found that it was a significant determinant of survival
after stroke.
We cannot be sure that the ascertainment of stroke was
complete. We retrieved information on stroke events through
GPs, nursing home physicians, and participants. For clinical
stroke, we believe we have complete ascertainment as we
screened 97% of all GP and nursing home records for stroke
events. The GP or nursing home physician would not have
been informed only if a patient did not seek medical
attention. Subclinical stroke however, presents without
clinical symptoms. The only accurate way of verifying the
completeness of stroke ascertainment would have been to
perform an MRI or CT scan of the brain of every participant.
Unfortunately, we did not have the equipment available to do
this. However, as incompleteness of follow up of stroke will
not have been dependent on genotype, we do not believe this
has biased our results.
We previously observed that non-carriers of the 192 bp
allele had lower levels of IGF-I compared with heterozygous
and homozygous carriers14 and that non-carriers of the IGF-I
gene were at higher risk of developing atherosclerosis and
MI.14 15 In this study, for any and ischaemic stroke, we found
a protective effect for non-carriers of the 192 bp allele,
although it was not significant. A possible explanation for
this may be that non-carriers die from MI before they can
develop a stroke. However, when we excluded prevalent and
incident MI from the analyses, the relative risk for any and
ischaemic stroke remained lower than 1. Another explana-
tion may be that there are more causes of ischaemic stroke
than large vessel atherosclerosis, which is in most cases the
sole cause of MI. When we subtyped ischaemic stroke into
Table 3 Relative risk of death after stroke in relation to IGF-1 genotype
IGF-1
Any stroke Ischaemic stroke Haemorrhagic stroke Unspecified
n RR (95% CI) n RR (95% CI) n RR (95% CI) n RR (95% CI)
192/192 144 1.0 (reference) 65 1.0 (reference) 15 1.0 (reference) 88 1.0 (reference)
192/2 135 1.1 (0.9 to 1.4) 65 1.2 (0.9 to 1.8) 19 0.9 (0.4 to 1.9) 73 1.1 (0.8 to 1.7)
2/2 37 1.5 (1.0 to 2.2)* 17 1.5 (0.9 to 2.6) 5 5.2 (1.3 to 21.5) 20 1.4 (0.7 to 2.4)
n, absolute numbers of death after stroke; RR, relative risk of death with 95% confidence intervals, adjusted for age and sex.
*p,0.05 compared with the reference group.
Table 4 Relative risk of cardiovascular death after stroke in relation to IGF-1 genotype
IGF-I
Any stroke Ischaemic stroke Haemorrhagic stroke Unspecified
n RR (95% CI) n RR (95% CI) n RR (95% CI) n RR (95% CI)
192/192 71 1.0 (reference) 32 1.0 (reference) 8 1.0 (reference) 31 1.0 (reference)
192/2 64 0.9 (0.7 to 1.3) 23 0.7 (0.4 to 1.3) 12 0.7 (0.3 to 1.9) 29 1.45 (0.9 to 2.5)
2/2 20 1.3 (0.8 to 2.2) 8 1.3 (0.6 to 2.9) 4 3.0 (0.6 to 14.5) 8 1.2 (0.5 to 2.9)
n, absolute numbers of cardiovascular death after stroke; RR, relative risk of cardiovascular death with 95% confidence intervals, adjusted for age and sex.
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large vessel disease, small vessel disease, and cardio-embolic
stroke according to the TOAST criteria,21 we found that non-
carriers had a relative risk of large vessel disease of 1.5 (95%
CI: 0.5 to 4.4), a relative risk of cardio-embolic stroke of 1.1
(95% CI: 0.5 to 2.5), and a relative risk of small vessel disease
of 0.5 (95% CI: 0.2 to 1.7). These results were not significant.
However, they do show that non-carriers are at higher risk of
stroke due to large vessel atherosclerosis (large vessel and
cardio-embolic stroke), while this is not the case for small
vessel stroke. This is also in concordance with earlier findings
in this study population that non-carriers of the 192 bp allele
had a significantly higher common carotid intima-media
thickness and a higher mean pulse wave velocity compared
with homozygous carriers,15 suggesting an association
between the IGF-I polymorphism and large vessel athero-
sclerosis.
Our study shows that the IGF-I promoter polymorphism is
a significant determinant of survival after any and haemor-
rhagic stroke. As our analyses of haemorrhagic stroke were
based on only five cases, the high estimate of the relative risk
of 5.20 should be interpreted with caution. We could not find
an association between IGF-I and survival in the overall
population, which suggests that IGF-I is a determinant of
survival specifically after stroke. The effect of IGF-I on
survival after stroke may again be due to the association with
MI, as it is one of the early causes of death after a stroke.24 25
In this study, we also found that the most important cause of
death after a stroke was cardiovascular disease. After any
stroke, 35.7% of the non-carriers died from cardiovascular
disease compared with 26.7% of homozygous carriers. After
haemorrhagic stroke, 67% of the non-carriers died of
cardiovascular disease compared with 36.4% of homozygous
carriers. Although the relative risk of CV death for non-
carriers was greater than 1 for all stroke groups, these
findings were not significant.
Another explanation could be related to the influence of
the 192 bp allele on IGF-I secretion. IGF-I is involved in brain
development.26 When neuronal loss occurs in the brain, levels
of IGF-I increase.8 It has been shown that IGF-I reduces
infarct volume and improves neurological function following
cerebral ischaemia, as IGF-I protects neurons from apoptosis
after diverse forms of injury.10 27 28 Non-carriers have lower
plasma IGF-I levels,14 and hence less neuroprotection, which
may lead to more severe handicap and higher case fatality
after ischaemic stroke. As we did not have data on handicap
after stroke, we were not able to test this hypothesis.
Our findings are in line with a recent study by Denti et al
who found that low levels of IGF-I are a significant predictor
of poor outcome, mainly death, after ischaemic stroke.11
However, it was unclear if low IGF-I levels were a cause or
a consequence of the poor outcome. Since we studied a gene
associated with IGF-I levels, we believe we have strong
evidence that low IGF-I levels are a cause and not a
consequence of the disease outcome. This indicates that
IGF-I might be used as a possible treatment for patients with
stroke. Indeed, several animal studies have found that
administration of IGF-I reduces infarct volume and improves
neurological function after ischaemia.8–10 27
In conclusion, in this large prospective population based
follow up study, we found that the IGF-I polymorphism was
a significant determinant of survival after any stroke.
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